Large-scale plasma proteomic profiling unveils diagnostic biomarkers and pathways for Alzheimer's disease

1. Research Background and Academic Significance Alzheimer’s Disease (AD) is the most common form of dementia worldwide, accounting for about 60–80% of all dementia cases. The primary affected population is individuals over 65 years old, with characteristic pathological features including the deposition of amyloid-β plaques, neurofibrillary tangles...

Large-Scale Network Analysis of the Cerebrospinal Fluid Proteome Reveals Molecular Signatures of Frontotemporal Lobar Degeneration

Analysis of Large-Scale Network Study of the CSF Proteome in FTLD — Unlocking Molecular Signatures of Neurodegenerative Diseases I. Academic Background and Motivation Frontotemporal Lobar Degeneration (FTLD) is one of the most common causes of early-onset dementia (under age 65), triggering a range of progressive behavioral, language, and even moto...

Development and Validation of a Proteomic Signature of Healthspan

1. Academic Background: From Lifespan Extension to the Enhancement of Healthspan With the improvement of global medical and socioeconomic standards since the 20th century, overall human lifespan has significantly increased, especially in developing countries. However, healthspan—the number of years an individual lives in a state of complete health,...

Fibroblast-Adipocyte Lineage Cell Interactions Result in Differential Production of Extracellular Matrix Proteins

Academic Background Scar formation is a common issue following trauma, burns, and other complications, significantly impacting the quality of life for millions of people worldwide. Fibroblasts play a central role in pathological scar formation, making them a common target for developing new therapies to promote healing and reduce scarring. Recent s...

ImmunoTar—Integrative Prioritization of Cell Surface Targets for Cancer Immunotherapy

Cancer remains one of the leading causes of death globally. Despite significant advancements in immunotherapy in recent years, such as the successful application of chimeric antigen receptor T-cell (CAR-T) therapy and antibody-drug conjugates (ADCs), the effective identification of cancer-specific surface protein targets remains a major challenge i...